Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4506 On Other Exchanges
Symbol
Exchange
4506 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ended Mar. 31, 2016; Announces an Year End Dividend for the Fiscal Year Ended Mar. 31, 2015, Payable on June 22, 2015

Sumitomo Dainippon Pharma Co., Ltd. provided dividend guidance for the fiscal year ended Mar. 31, 2016. For the year, the company expects to pay a dividend of ¥9 per share at the end of the second quarter and ¥9 per share at the end of the year, making a total dividend of ¥18 per share for fiscal 2015 against the same amount of dividend for the last year. The company also announced an year end dividend of ¥9 per share for the fiscal year ended Mar. 31, 2015. Starting date of dividend payments is June 22, 2015.

Sumitomo Dainippon Pharma Co., Ltd. Reports Consolidated Earnings Results for the Full Year Ended March 31, 2015; Provides Earnings Guidance for the Six Months Ending September 30, 2015 and Full Year Ending March 31, 2016

Sumitomo Dainippon Pharma Co., Ltd. reported consolidated earnings results for the full year ended March 31, 2015. For the year, the company reported net sales of JPY 371,370 million compared to JPY 387,693 million a year ago. Operating income was JPY 23,275 million compared to JPY 42,142 million a year ago. Ordinary income was JPY 23,331 million compared to JPY 40,631 million a year ago. Net income was JPY 15,447 million or JPY 38.88 per share compared to JPY 20,060 million or JPY 50.49 per share a year ago. ROE was 3.6% compared to 5.4% a year ago. Net cash provided by operating activities was JPY 30,251 million compared to JPY 49,943 million a year ago. Purchases of property, plant and equipment was of JPY 8,662 million compared to JPY 10,332 million a year ago. Income before income taxes and minority interests were of JPY 33,755 million compared to JPY 34,709 million a year ago. EBITDA was JPY 43.1 billion compared to JPY 68.1 billion a year ago. Capital expenditures were of JPY 9.7 billion compared to JPY 13.5 billion. The company provided earnings guidance for the six months ending September 30, 2015 and full year ending March 31, 2016. For the six months, the company expects net sales of JPY 193,000 million, operating income of JPY 11,000 million, ordinary income was JPY 11,000 million and net income attributable to owners of parent of JPY 8,000 or JPY 20.14 per share. The company expects EBITDA of JPY 21.5 billion and ROE of 1.8%. For the year, the company expects net sales of JPY 392,000 million, operating income of JPY 27,000 million, ordinary income was JPY 26,500 million and net income attributable to owners of parent of JPY 18,000 or JPY 45.31 per share. The company expects EBITDA of JPY 47.5 billion and ROE of 4.0%. The company expects capital expenditures of JPY 11.5 billion.

Sumitomo Dainippon Pharma Co., Ltd., 2015 Pre Recorded Earnings Call, May 18, 2015

Sumitomo Dainippon Pharma Co., Ltd., 2015 Pre Recorded Earnings Call, May 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,410.00 JPY +4.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.77 USD +0.03
FUJIFILM Holdings Corp ¥4,712 JPY +28.00
GlaxoSmithKline Consumer Nigeria PLC 44.00 NGN 0.00
Pernix Therapeutics Holdings Inc $6.38 USD -0.13
Teva Pharmaceutical Industries Ltd $61.05 USD -0.37
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 35.7x
Price/Sales 1.5x
Price/Book 1.2x
Price/Cash Flow 26.9x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.